BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...By BioCentury Staff AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million...
...combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc....
Items per page:
1 - 2 of 2
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...By BioCentury Staff AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million...
...combination with traditional therapeutics to treat cognitive and neurobehavioral disorders. TARGETSTF (CD142; thromboplastin) – Tissue factor BC Staff Genesis Therapeutics Inc. AbbVie...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc....
Items per page:
1 - 2 of 2